This site is part of the Informa Connect Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC's registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 3099067.

TIDES Europe: Oligonucleotide and Peptide Therapeutics
11-13 November 2025
Congress Center BaselBasel, Switzerland

Dr. Tsuyoshi Yamamoto, PhD
CSO at Liid Pharmaceuticals
Speaker

Profile

Dr. Yamamoto obtained his degree from the Graduate School of Pharmaceutical Sciences at Osaka University in 2012, under the mentorship of Professor Satoshi Obika. After graduating, he became an Assistant Professor of the Obika Lab. In 2015, Dr. Yamamoto broadened his research experience by joining the Martin Schnermann Laboratory at the National Institute of Health in the U.S. In 2018, he was appointed as an Associate Professor at the Graduate School of Biomedical Sciences at Nagasaki University, working in Professor Asako Yamayoshi's Lab. Beyond his academic pursuits, Dr. Yamamoto is also involved in the clinical application development at Liid Pharmaceuticals Inc., an oligo drug startup originating from the National Cerebral and Cardiovascular Center in Japan.

Awards: The Nucleic Acids Therapeutics Society of Japan (NatsJ) Award for Young Scientists (2022)

Agenda Sessions

  • BROTHERS: A Proprietary Antisense Oligonucleotide Platform for the Treatment of a Broader range of Diseases

    11:50